ARTICLE / CLIENT ALERT / US POLICY
Biden Administration Executive Order Requires Project Labor Agreements with Unions on Certain Federal Construction Projects
February 17, 2022
Read time: 3 min
A project labor agreement (PLA) is a collective bargaining agreement between a contractor and the building trade union on a specific construction project. PLAs are negotiated before any workers are hired, and they establish the terms of employment on a project. Executive Order (EO) 14063, issued by the Biden administration on February 2, 2022, requires PLAs on “large-scale construction projects,” defined as Federal construction projects within the United States for which the total estimated cost of the construction contract to the Federal Government is at least $35 million.
EO 14063 provides that PLAs must include specific terms. PLAs must (a) allow all contractors and subcontractors on the project to compete for project work whether or not they are otherwise unionized; (b) contain guarantees against strikes, lockouts and similar job disruptions; (c) establish mutually binding dispute resolution methods; (d) provide other mechanisms for cooperation between labor and management; and (e) fully conform to all statutes, regulations, executive orders and presidential memoranda.
All contractors and subcontractors that work on the construction project are subject to the PLA, and its terms supersede any of their existing collective bargaining agreements. Although the PLA binds all parties and applies to all workers on the construction project, it does not require that the contractor itself unionize.
Notably, the EO allows a “senior official” within an agency the discretion to grant exceptions to the requirement for PLAs when:
- Requiring a PLA on the project would not advance the Federal Government’s interests in achieving economy and efficiency in Federal procurement based on certain specified factors;
- Based on market analysis, requiring a PLA on the project would substantially reduce the number of potential bidders to frustrate full and open competition; or
- Requiring a PLA on the project would otherwise be inconsistent with statutes, regulations, executive orders or presidential memoranda.
EO 14063 is a significant leap from EO 13502, a 2009 Obama administration EO that merely “encourage[d]” Federal agencies to mandate PLAs on large-scale construction projects. A final rule implementing EO 13502, effective as of May 13, 2010, granted Federal executive agencies discretion to require use of PLAs on a project-by-project basis. EO 14063 revokes EO 13502 as of the effective date of the implementing final regulations.
WHAT HAPPENS NOW?
The Federal Acquisition Regulatory Council has 120 days to propose regulations implementing EO 14063.
***************
McDermott Will & Emery is closely tracking developments in this matter and assisting federal contractors with strategy and compliance efforts related to these developments. Please do not hesitate to reach out to the authors of this article or your McDermott Will & Emery lawyer for more information.

2022 IP Outlook Report: The Developments Shaping Patent Law
ARTICLE / REPORT
2022 IP Outlook Report: The Developments Shaping Patent Law
February 17, 2022
Read time: 2 min
Tracking with this era’s continuation and uncertainty trends―global supply chain disruption, innovation outpacing legislation, the unstoppable internet of [all the] things (IoT)―2022 is expected to be another busy year in the world of patent litigation.

Restrictive Covenants Evolve From Common Law to Statutory Regulation: The 2022 Watershed
ARTICLE
Restrictive Covenants Evolve From Common Law to Statutory Regulation: The 2022 Watershed
February 17, 2022
Read time: 2 min
McDermott lawyers, Brian Mead and Aaron Sayers wrote this bylined article in Westlaw Today where they share insight into state legislation changes regarding restrictive covenants and what employers in certain states should keep in mind when reevaluating their agreements.
2021 Digital Health Year in Review
ARTICLE / REPORT
2021 Digital Health Year in Review
February 2022
Read time: 2 min
The continuation of the COVID-19 public health emergency (PHE) and consumer demand for digitally delivered healthcare not only necessitated the shift from in-person to virtual care, but also continued to drive interest, adoption, investment and transactions in digital health in 2021. Digital health funding in 2021 far surpassed 2020’s totals with no signs of slowing down in 2022, and the potential permanence of some regulatory flexibilities beyond the PHE are charting a course for continued digital health growth in 2022 and beyond.
This Digital Health Report explores issues to monitor as you chart a path forward in 2022, including:
- Telehealth Regulatory Updates Shaping Care Delivery, Reimbursement and Business Models
- Interoperability and Data Sharing
- Health Privacy and Enforcement, from HIPAA to Consumer Data Protection Laws
- What to Watch in Dealmaking
COVID-19 Vaccination Approvals: A Legal and Bioethical Framework
ARTICLE
COVID-19 Vaccination Approvals: A Legal and Bioethical Framework
February 14, 2022
Read time: 2 min
“On February 24, 2022, the American Health Law Association (AHLA) will be hosting a webinar, “COVID-19 Vaccination Approvals: A Legal and Bioethical Framework.” The program will focus, among other things, on the U.S. Food and Drug Administration (FDA) vaccine approval process, how the practice of medicine permits off label uses for FDA-approved products (but not Emergency Use Authorizations (EUA)), the challenges of operating within the confines of an EUA, and other life sciences aspects of using pharmaceuticals to quell the COVID-19 pandemic. This paper provides a prelude synopsis of these topics.”

New Developments in Real Estate Business Law – Changes in 2022 and Plans of the New Federal Government
ARTICLE / CLIENT ALERT
New Developments in Real Estate Business Law – Changes in 2022 and Plans of the New Federal Government
February 2022
Read time: 2 min
The new year holds some important legislative changes for the real estate industry that require your attention. In our Real Estate Update, we would like to provide you with the most important information at a glance on some selected legislative changes that have already come into force and are likely to come into force in the future. To this end, we also take a look at the coalition agreement for you.

New Nationwide Ban against the Enforcement of Mandatory Arbitration Agreements in Sexual Misconduct Cases
ARTICLE / CLIENT ALERT
New Nationwide Ban against the Enforcement of Mandatory Arbitration Agreements in Sexual Misconduct Cases
February 15, 2022
Read time: 5 min
On February 10, 2022, the US Senate passed the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act of 2021 (the Act), a bipartisan bill that invalidates and renders unenforceable predispute arbitration agreements in any case alleging sexual assault or sexual harassment. The US House of Representatives passed a version of the bill on February 7, 2022. US President Joe Biden is expected to sign the bill into law soon.
A number of states previously passed similar legislation barring mandatory arbitration provisions of sexual misconduct claims but were subject to preemption under the Federal Arbitration Act (FAA), which provides that arbitration agreements (like other contracts) “shall be valid, irrevocable, and enforceable” unless they are the product of fraud or unconscionability or are otherwise unenforceable as a matter of generally applicable contract law. The Act is not subject to any such preemption defense.
The Act does not, however, forbid arbitration on other claims between employers and employees. Employers can, and should, continue to use predispute arbitration agreements (whether they expressly exclude sexual misconduct claims or not) with the understanding that they will be unable to enforce arbitration of sexual misconduct claims without the employee’s consent. Employers should also review applicable state laws governing arbitration that may prohibit mandatory arbitration of other employment claims, although such state laws risk being preempted by the FAA.
WHAT THE ACT DOES AND DOES NOT COVER
The Act bans employers from enforcing predispute arbitration agreements to arbitrate claims of sexual assault and sexual harassment, whether brought in an individual capacity or in a joint, class or collective action.
The pending law also dictates that any dispute over the Act’s application to an employee’s claims (issue of arbitrability) must be decided by a court, not an arbitrator—even where the arbitration agreement attempts to delegate such authority to an arbitrator. Any disputes over arbitrability will also be governed by federal law. It remains unclear whether the Act could later be extended to claims for gender discrimination.
Although the Act bars employers from mandating that employees arbitrate sexual misconduct claims, it does not ban employees from electing to arbitrate claims for sexual assault and sexual harassment, an acknowledgment that some employees would prefer to privately arbitrate their dispute over publicly litigating it in court. Under the Act, the decision as to which form of dispute resolution to choose rests entirely with the employee.
The soon-to-be law will apply retroactively. Therefore, to the extent current employees are subject to arbitration agreements that require them to arbitrate sexual harassment or sexual assault disputes, employers will no longer be able to enforce such agreements in relation to those claims.
THE ACT FOLLOWS A TREND THAT BEGAN AT THE STATE LEVEL
While the Act is the first of its kind at the federal level, several states already enacted state law prohibiting enforcement of arbitration agreements against employees claiming sexual assault and/or sexual harassment in the wake of the #MeToo movement. In 2018, New York passed a law amending the state’s Civil Practice Law and Rules (CPLR), which govern legal procedure in the New York unified court system, to make predispute agreements to arbitrate sexual harassment claims illegal and unenforceable. (N.Y. C.P.L.R. Art. 75 §7515.) That same year, Vermont took a more nuanced approach, amending the state’s employment regulations to set limitations on what employers can mandate in employment contracts related to sexual harassment generally. (21 Vt. Stat. Ann. §495h (2018), amended by Vt. H.B. 707 (May 28, 2018) (prohibiting employers from requiring employees to sign any agreement or waiver as a condition of employment that restricts them from participating in an investigation or purporting to waive a substantive or procedural right or remedy and requiring that any agreement to settle a claim of sexual harassment expressly state that it does not restrict the employee’s rights to pursue any other kind of relief).)
WHAT THIS MEANS FOR EMPLOYERS
Employers can continue using their current mandatory arbitration agreements, even if they do not expressly carve out an exception for sexual harassment and sexual assault claims, so long as they do not enforce the agreement in the event that an employee raises such a claim and chooses to litigate in court.
Alternatively, some employers, particularly those with operations in states that have similar restrictions against compelling sexual misconduct disputes to arbitration, may choose to revise their current arbitration agreements to exempt sexual harassment and sexual assault from arbitration in the same way that state workers’ compensation claims or federal Employee Retirement Income Security Act (ERISA) claims are exempt from arbitration.
Complaints filed against employers routinely contain numerous causes of action. Employers faced with hybrid litigation that involve sexual misconduct and non-sexual misconduct claims should also consider seeking a court order to “stay” the non-arbitrable sexual misconduct claims pending resolution of the remaining claims in arbitration.

Treasury Responds to Biden Administration Executive Order with Report, Recommendations to Increase Alcohol Industry Competition
ARTICLE / CLIENT ALERT
Treasury Responds to Biden Administration Executive Order with Report, Recommendations to Increase Alcohol Industry Competition
February 15, 2022
Read time: 6 min

On February 9, 2022, the US Treasury Department (Treasury) released a report with recommendations for how the Tobacco Tax and Trade Bureau (TTB), Federal Trade Commission (FTC) and Department of Justice (DOJ) can help drive competition in the beer, wine and spirits markets by stepping up conduct enforcement, adopting creative and nuanced theories of harm in merger reviews and implementing new regulations to decrease the burden on smaller industry participants.
TREASURY REPORT SUMMARY
- Treasury released a report entitled “Competition in the Markets for Beer, Wine, and Spirits” in response to President Biden’s July 2021 Executive Order 14036 that assesses the current market structure and conditions of competition, including an assessment of threats to competition and barriers to entry.
- Treasury’s report is based, in part, on hundreds of comments received from industry participants and paints a detailed picture of the current landscape for alcohol beverage distribution and sale across the United States.
- The report focuses on how changes could benefit smaller participants in the beer, wine and spirits industry. Given that the stated goal of Executive Order 14036 was, in part, “to reduce the trend of corporate consolidation, increase competition, and deliver concrete benefits to America’s consumers, workers, and small businesses,” it is not surprising that the report is focused on analyzing how a shift in enforcement priorities may be able to help eliminate impediments that make it difficult for smaller producers, distributors and retailers to compete with the larger players in the industry. Treasury specifically recommends that TTB cease bringing cases against “smaller industry members whose conduct does not have obvious effects on competition” (i.e., the investigation several years ago against small wineries for ‘consignment sales’).
- Treasury makes recommendation on enforcement priorities for FTC, DOJ and TTB. To address the market concentration concerns that the report describes, Treasury makes recommendations regarding how the TTB, FTC and DOJ should focus investigations and enforcement of mergers and conduct in each of the three tiers of the beer, wine and spirits markets: producers, distributors and retailers.
- Many of the recommendations are likely to be pursued given that the Attorney General and FTC Chair were consulted. The report and its recommendations should be considered carefully as a clear indication of the kinds of issues that FTC and DOJ are likely to focus their investigations on in beer, wine and spirits because the report was developed “in consultation with the Attorney General [DOJ] and the Chair of the FTC.”
TREASURY’S KEY RECOMMENDATIONS
- While there are myriad competition-focused suggestions in the report, we think the areas that are most likely to receive increased focus from FTC, DOJ and TTB are the following:
- Anticompetitive Conduct: Treasury noted that FTC, DOJ and TTB have generally not brought any conduct cases on many theories of harm for which myriad complaints were received. Treasury suggests that TTB should act on these complaints and seek support from FTC and DOJ to bring joint cases and make use of the agencies’ combined and complementary authority. These three areas are likely to already be under scrutiny by TTB and will chart a new direction for enforcement priorities.
- Category Management: Despite current TTB regulations preventing producers and distributors from providing more than “suggested shelf schematics” to retailers, Treasury noted there are many complaints of large producers and distributors acting as category captains and eroding the independence of retailers (through inducements or simply by controlling the planogram software), and this conduct may be hampering competition, reducing consumer choice and resulting in higher prices.
- Tying: Despite a history of investigating tying arrangements, Treasury noted that no cases have been brought recently. Treasury, therefore, identified tying as an area for focus given the myriad complaints it has received regarding this kind of conduct—e.g., (i) distributor requires a retailer to buy undesired brands as a condition of buying its desired brands or (ii) a distillery requires a distributor to buy its non-premium brands as a condition to gaining access to the highly sought brand. This could also be an area of future focus with companies using non-alcoholic brands to leverage purchases in the alcoholic space.
- Exclusive Conduct: A dominant distributor uses exclusive contracts with suppliers to impede effective competition by smaller distributors.
- Mergers: In addition to continuing to analyze traditional competitive effects of transactions (horizontal overlaps) between producers or distributors, the report encourages investigating more nuanced theories of competitive effects:
- Portfolio Effects (for example, a major brewer acquires craft brands):
- Reducing incentives for distributors to carry or support other small craft brewers; and/or
- Increasing the power of the brewer to receive added support from dominant distributors at the expense of smaller brewers.
- Non-Geographic Overlaps:
- When multistate distributors acquire distributors in new geographies, they can use their leverage to force producers to expand with it; or
- If a distributor acquires a producer’s franchise distributor, it can then threaten harm to the producer if it attempts to move its business away in the non-franchise states.
- Portfolio Effects (for example, a major brewer acquires craft brands):
- Greater Transparency: Reworking laws and regulations to increase transparency with consumers and thereby increase competition and/or lower burden on smaller producers/participants:
- TTB should engage in rulemaking on labeling, including ingredients, calorie and nutritional content, allergens, serving sizes and container sizes.
- TTB should engage in rulemaking to eliminate container size requirements.
- Revise complex application requirements to qualify for a permit to produce alcohol.
- Anticompetitive Conduct: Treasury noted that FTC, DOJ and TTB have generally not brought any conduct cases on many theories of harm for which myriad complaints were received. Treasury suggests that TTB should act on these complaints and seek support from FTC and DOJ to bring joint cases and make use of the agencies’ combined and complementary authority. These three areas are likely to already be under scrutiny by TTB and will chart a new direction for enforcement priorities.
WHAT THIS MEANS
- Given Treasury’s recommendations (and the tenor of the industry comments it quoted in the report), we expect TTB, together with FTC and DOJ, to shift its trade practice enforcement efforts and increase its scrutiny of conduct and mergers involving a large (particularly beer) producer or multistate distributor.
- We expect increased enforcement with regard to category management, tying arrangements and exclusive contracts on large producers and distributors.
- We also expect FTC and DOJ to closely review the impact of any mergers involving multistate distributors or large producers under theories of harm that are not typically investigated.

Pending Supreme Court Decision in AHA v. Becerra May Be Felt Well Beyond the Healthcare Industry
ARTICLE / CLIENT ALERT
Pending Supreme Court Decision in AHA v. Becerra May Be Felt Well Beyond the Healthcare Industry
February 15, 2022
Read time: 8 min
By July 2022, the US Supreme Court is expected to release its opinion in American Hospital Association v. Becerra, a case that not only has significant ramifications for healthcare providers but may also impacts the deference all federal courts give to agency interpretations of ambiguous statutes (also known as the Chevron doctrine).
STAY CURRENT ON THE 340B LITIGATION THAT MAY IMPACT YOUR BUSINESS
McDermott+Consulting has launched a 340B Litigation Tracking Tool, a real-time resource following the 40+ state and federal 340B program legal challenges. No more searching online or sorting through your newsfeed for important case developments. This tracker, available 24/7 and regularly monitored by our team, delivers concise updates to help you make informed risk analyses on what’s next for your business in the evolving 340B landscape. Learn more here.
The US Supreme Court will issue its much-anticipated opinion in American Hospital Association v. Becerra by the end of its current term (June or July 2022). The American Hospital Association’s (AHA) appeal in the case challenges a decision by the US Court of Appeals for the District of Columbia Circuit upholding the US Department of Health and Human Services’ (HHS) final rule reducing Medicare reimbursement for 340B drugs. While the case has significant ramifications for many hospitals that participate in the 340B Program, the implications of the opinion may be much more broad. At its core, the case is not about payments for 340B drugs, it is a vehicle for the Supreme Court to consider the vitality and scope of the Chevron doctrine of judicial deference to agency interpretations of ambiguous statutes.
The Statutory Arguments in Depth
The 340B Program helps certain “covered entities”—including many hospitals—stretch scarce federal resources by allowing the entities to purchase certain eligible outpatient drugs from manufacturers at a discount.
The Social Security Act provides that the amount that the Centers for Medicare & Medicaid Services (CMS) pays hospitals for outpatient drugs under the Medicare Outpatient Hospital Prospective Payment System (OPPS) is equal:
- “(I) to the average acquisition cost [(AAC)] for the drug for that year (which, at the option of the Secretary [of HHS], may vary by hospital group (as defined by the Secretary based on volume of covered [outpatient department] OPD services or other relevant characteristics)), as determined by the Secretary taking into account the hospital acquisition cost survey data under subparagraph (D); or
- “(II) if hospital acquisition cost data are not available, the average price for the drug … as calculated and adjusted by the Secretary as necessary for purposes of this paragraph.” (42 U.S.C. §1395l(t)(14)(A)(iii)(I) – (II) (emphasis added).)
From 2006 to 2017, HHS calculated reimbursement rates based on the average sales price (ASP) of the drug. HHS used the ASP instead of the AAC of the drug because HHS lacked hospital acquisition cost survey data. This method resulted in all hospitals paid under OPPS, including 340B-participating hospitals paid under OPPS, receiving reimbursement equal to 104% to 106% of the ASP for outpatient drugs.
In 2018, HHS issued a final rule providing that HHS may reimburse 340B hospitals for outpatient drugs paid under OPPS at an amount intended to approximate the 340B-discounted AAC, rather than an amount based on ASP. The final rule recognized that the Secretary has the discretion to vary reimbursement by hospital group based on the volume of covered outpatient services or other relevant characteristics. It also provided that in cases of insufficient data, the HHS Secretary may “calculate and adjust the reimbursement amount as necessary for the purposes of the statute.” The final rule reduced payments to 340B hospitals to 77.6% of ASP, which was a reduction of approximately 30% from the 106% of ASP that they received previously.
AHA asserts that the rate change exceeds the bounds of an “adjustment” authorized by the statute. That is, AHA maintains that HHS lacks the statutory authority to base reimbursement on AAC in the absence of cost-survey data and cannot vary price-based rates by hospital group. According to AHA, Congress included the survey requirement to ensure accurate, consistent and transparent calculation of reimbursement rates. By eliminating that requirement, HHS acted in excess of its statutory authority and contrary to Congress’s intent.
AHA similarly argues that the final rule is not defensible under Chevron because the statute is clear and unambiguous. Congress required a cost survey if rates are based on AAC, or varied by hospital group, and Congress did not authorize HHS to waive the requirement.
AHA urges the Court to approach Chevron deference much like it approached Auer deference in Kisor v. Wilkie (139 S. Ct. 2400 (2019)). Auer deference is the judicial doctrine of deferring to an agency’s reasonable reading of its own genuinely ambiguous regulations. In Kisor, the Court retained the doctrine, but held that the lower courts must exhaust the canons of regulatory interpretation before applying the doctrine to genuinely ambiguous regulations.
AHA submits that the Court should similarly exhaust its statutory interpretation toolkit—taking into consideration the language, structure, operation and provenance of the 340B statute—before deferring to HHS’s interpretation of the statute under Chevron. The view of the AHA is that the statute is unambiguous and no resort to Chevron deference is necessary. If HHS wants to distinguish its reimbursement methodology across hospital categories, it must follow the statute and conduct a cost survey, or get Congress to change the law.
In contrast, HHS argues that the unambiguous statutory language gives HHS the discretion to set the reimbursement rate at AAC. If cost survey data is unavailable, then the Secretary of Health and Human Services may “calculate and adjust rates as necessary for the purposes of the statute.” The rate change is an adjustment that is supported by evidence and vindicates the purpose of the statute, which is to align reimbursement rates with acquisition costs as closely as possible. HHS maintains that the Court would reach the same outcome by applying Chevron, just as the D.C. Circuit did. The D.C. Circuit concluded that Congress had not unequivocally barred HHS from adjusting reimbursement, and HHS’s view was not patently unreasonable.
The Future of Chevron Deference
This case presents the Supreme Court with an opportunity to consider the vitality of Chevron and the limitations on its application. Indeed, some commentators were surprised that the Court granted certiorari in the case and assume that it did so in order to reassess Chevron (For a sample of these discussions, see here, here and here.).
The Court has several options available to it. First, affirm the decision and reasoning of the DC Circuit Court, which embraced a framing of Chevron that is favorable to the government. Second, overturn Chevron. Third, take a page from Kisor by preserving Chevron and reinvigorating the limits on its application. The second option would shift power from the executive branch to the legislative and judicial branches and create a stronger incentive for Congress to draft legislation that is both comprehensive and clear. The third option would as well, albeit to a lesser degree.
Amicus briefs were filed by a variety of stakeholders, including trade associations representing not only healthcare providers but also entirely different regulated industries. Many healthcare providers argued that 340B hospitals deliver care to underserved and disadvantaged patients, and therefore should not bear the brunt of a rate cut. Other healthcare providers (mainly hospitals ineligible for the 340B program) argued that HHS’s interpretation recaptures dollars that were previously reserved for 340B hospitals, and reallocates those dollars across all acute care hospitals paid under the OPPS system, which furthers the original goal of the OPPS system by incentivizing the efficient delivery of outpatient services.
Stakeholders outside of the healthcare industry typically opined on the scope and vitality of Chevron. Some argued that Chevron presents separation of powers concerns because it enlarges the executive branch at the expense of the legislative and judicial branches. The unintended consequence of Chevron is that it incentivizes Congress to pass ambiguous laws and avoid accountability by handing off complicated policy decisions to unelected agency personnel. Additional stakeholders argued that agency personnel may not be impartial and Chevron enables political interference with the implementing of statutes. Other stakeholders generally supported the preservation of Chevron and argued that it is consistent with separation of powers and does not lead to an expansion of the administrative state when applied appropriately.
At oral argument, the Supreme Court justices repeatedly raised questions about the vitality of Chevron. Justices Kagan, Sotomayor and Breyer raised questions suggesting that they do not believe that this is the case to overturn Chevron. Justices Gorsuch, Kavanaugh and Barrett questioned whether the ambiguity in the statute raises a simple interpretive question that the Court should resolve, or an issue requiring Chevron analysis and implicating delegation to an agency. None of the questioning suggested that a majority of the justices will vote to overrule Chevron.
We will await the Supreme Court’s opinion and follow up with an update once it is published.

State Law Privacy Video Series | Opt-Out Rights
ARTICLE / CLIENT ALERT / VIDEO
State Law Privacy Video Series | Opt-Out Rights
February 15, 2022
Read time: 2 min
California, Virginia and Colorado have new privacy laws coming into effect in 2023. But now is the time to start preparing your business or organization for compliance.
In this video series, we examine the different aspects of these laws and provide you the knowledge and tools you need for proper compliance.
In this video, Associate Fran Forte reviews the new opt-out rights offered to consumers under each state law, as well as the key implementation requirements businesses should be aware of.

